Safety Study of SEA-CD40 in Cancer Patients
Public ClinicalTrials.gov record NCT02376699. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is being done to find out if SEA-CD40 is safe and effective when given alone, in combination with pembrolizumab, and in combination with pembrolizumab, gemcitabine, and nab-paclitaxel. The study will test increasing doses of SEA-CD40 given at least every 3 weeks to small groups of patients. The goal is to find the highest dose of SEA-CD40 that can be given to patients that does not cause unacceptable side effects. Different dose regimens will be evaluated. Different methods of administration may be evaluated. The pharmacokinetics, pharmacodynamic effects, biomarkers of response, and antitumor activity of SEA-CD40 will also be evaluated.
Study identification
- NCT ID
- NCT02376699
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 159 participants
Conditions and interventions
Conditions
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous Cell
- Hodgkin Disease
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Melanoma
- Neoplasm Metastasis
- Neoplasms, Head and Neck
- Neoplasms, Squamous Cell
- Non-Small Cell Lung Cancer
- Non-Small Cell Lung Cancer Metastatic
- Non-small Cell Carcinoma
- Squamous Cell Cancer
- Squamous Cell Carcinoma
- Squamous Cell Carcinoma of the Head and Neck
- Squamous Cell Neoplasm
- Lymphoma, Non-Hodgkin
- Pancreatic Adenocarcinoma
Interventions
- Intravenous (IV) SEA-CD40 Drug
- Pembrolizumab Drug
- Subcutaneous (SC) SEA-CD40 Drug
- Gemcitabine Drug
- Nab-paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2015 (Actual)
- Primary completion
- Mar 6, 2023 (Actual)
- Completion
- Apr 14, 2023 (Actual)
- Last update posted
- May 1, 2023
2015 – 2023
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35249 | — |
| HonorHealth Scottsdale Shea Medical Center | Scottsdale | Arizona | 85258 | — |
| Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute | Los Angeles | California | 90048 | — |
| Angeles Clinic and Research Institute, The | Santa Monica | California | 90404 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637-1470 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute / Wayne State University | Detroit | Michigan | 48201 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| University of New Mexico Cancer Center | Albuquerque | New Mexico | 87131 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| UNC Lineberger Comprehensive Cancer Center / University of North Carolina | Chapel Hill | North Carolina | 27599 | — |
| Case Western Reserve University / University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| MD Anderson Cancer Center / University of Texas | Houston | Texas | 77030-4095 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
| Seattle Cancer Care Alliance / University of Washington | Seattle | Washington | 98109-1023 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02376699, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 1, 2023 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02376699 live on ClinicalTrials.gov.